1. The increase in inventory could partially be be
Post# of 36537
(Total Views: 257)
Posted On: 12/16/2019 11:18:43 PM
1. The increase in inventory could partially be because now GNBT's inventory includes inventory for Pantheon and Medisource.
2. One really positive thing I noticed in the 10Q is the gross margin is approximately 81%. This means the cost of goods is really low. For people who do not have a finance background...this means for every $100 GNBT sells, the cost is only $19, and $81 goes toward operating/admin expenses. So, if Joe's revenue number after fully funded is correct - $250 million revenue...that means 81% or $202.5 million will go to expenses...the company can possibly have substantial profit once GNBT increase its revenue.
Buildit wrote -
1) Finished Goods was built up by 130% or $367k. Hopefully this is largely Excellagen, and they are selling somewhat significant quantities now (relative to the paltry amount apparently sold in this Q).
Does anyone happen to know what the FG accounting method is? If it's a fairly std cost valuation, and it's primarily Excellagen as I hope, this could represent ~$15MM in potential revs. As Excellagen has a shelf life (can't remember, 3 months?), maybe this bodes well for the next Q. Anyone have any knowledge to add to this line of thinking?
2) Olaregen acquisition payments have ALL been officially postponed to 1/31/20. Maybe that date was chosen because they hope the S-1 $ will be available by then. Whatever the case we are not in arrears on payments for the asset that is most likely to produce short-term revs... which do matter, IMHO.
Read More: https://investorshangout.com/post/newpost/622...z68KlUNAPA
2. One really positive thing I noticed in the 10Q is the gross margin is approximately 81%. This means the cost of goods is really low. For people who do not have a finance background...this means for every $100 GNBT sells, the cost is only $19, and $81 goes toward operating/admin expenses. So, if Joe's revenue number after fully funded is correct - $250 million revenue...that means 81% or $202.5 million will go to expenses...the company can possibly have substantial profit once GNBT increase its revenue.
Buildit wrote -
1) Finished Goods was built up by 130% or $367k. Hopefully this is largely Excellagen, and they are selling somewhat significant quantities now (relative to the paltry amount apparently sold in this Q).
Does anyone happen to know what the FG accounting method is? If it's a fairly std cost valuation, and it's primarily Excellagen as I hope, this could represent ~$15MM in potential revs. As Excellagen has a shelf life (can't remember, 3 months?), maybe this bodes well for the next Q. Anyone have any knowledge to add to this line of thinking?
2) Olaregen acquisition payments have ALL been officially postponed to 1/31/20. Maybe that date was chosen because they hope the S-1 $ will be available by then. Whatever the case we are not in arrears on payments for the asset that is most likely to produce short-term revs... which do matter, IMHO.
Read More: https://investorshangout.com/post/newpost/622...z68KlUNAPA
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼